一个下一代的HDAC6抑制剂用于肌缩侧面硬化和前性痴呆症
Rebecca E James1, Michael Bekier2, Pin-Tsun Justin Lee3
1Eikonizo Therapeutics, Inc., Cambridge, MA 02142, USA.
Brain : a journal of neurology
|October 8, 2025
概括
一种新药,EKZ-438,通过选择性抑制HDAC6.6来治疗ALS和FTD等神经退行性疾病,显示出有希望的结果. 这改善了蛋白质静止和细胞内运输,在临床前模型中提供神经保护.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不调节的蛋白质静止和细胞内运输是神经退行性疾病的标志.
- HDAC6 (基因组脱乙酶6) 是这两种过程的关键调节剂,也是治疗点.
- 第一代HDAC6抑制剂缺乏选择性和透到中枢神经系统 (CNS),阻碍了临床进展.
研究的目的:
- 描述EKZ-438,一个下一代选择性HDAC6抑制剂.
- 评估EKZ-438在肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 的临床前模型中的疗效.
- 确定选择性HDAC6抑制是否可以挽救蛋白质静止和细胞内运输缺陷.
主要方法:
- 药理学特征EKZ-438的选择性,效力,中枢神经系统透性和口服生物可用性.
- 在体外和体内研究中使用ALS和FTD的细胞和动物模型 (SOD1G93A,TDP-43模型).
- 评估蛋白质静止,细胞内运输,运动神经元存活,运动性能和神经炎症标志物.
主要成果:
- EKZ-438显示出高选择性 (>8,500倍),低纳米分子功效 (12nM),良好的中枢神经系统透率 (≥0.55),以及高口服生物可用性 (70%).
- 在ALS模型中,用EKZ-438治疗挽救了蛋白质稳定缺陷,增强了运动神经元存活率,改善了轴突运输和运动性能.
- 在FTD模型中,EKZ-438降低了TDP-43病理和神经炎症,并在人类iPSC衍生的神经元中挽救了细胞内运输和神经元存活率.
结论:
- 通过EKZ-438选择性抑制HDAC6足以改善ALS和FTD模型中的蛋白质静止和细胞内运输缺陷.
- EKZ-438在体外和体内表现出显著的神经保护作用,支持其治疗潜力.
- EKZ-438代表了对ALS和FTD潜在疾病修饰的有前途的治疗策略.
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
Amyloid Fibrils
6.3K
6.3K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
983
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
983


